Last Updated: November 18, 2026

Acetaminophen; oxycodone hydrochloride; oxycodone terephthalate - Generic Drug Details

« Back to Dashboard


What are the generic sources for acetaminophen; oxycodone hydrochloride; oxycodone terephthalate and what is the scope of patent protection?

Acetaminophen; oxycodone hydrochloride; oxycodone terephthalate is the generic ingredient in one branded drug marketed by Ortho Mcneil Pharm and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for acetaminophen; oxycodone hydrochloride; oxycodone terephthalate
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
DailyMed Link:acetaminophen; oxycodone hydrochloride; oxycodone terephthalate at DailyMed
Anatomical Therapeutic Chemical (ATC) Classes for acetaminophen; oxycodone hydrochloride; oxycodone terephthalate

US Patents and Regulatory Information for acetaminophen; oxycodone hydrochloride; oxycodone terephthalate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ortho Mcneil Pharm TYLOX acetaminophen; oxycodone hydrochloride; oxycodone terephthalate CAPSULE;ORAL 085375-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Acetaminophen and Oxycodone Hydrochloride Market Dynamics, Financial Trajectory, and Patent Risk

Last updated: November 11, 2026

The acetaminophen and oxycodone hydrochloride market is a mature, largely generic opioid market with declining prescription volume, severe regulatory constraints, and limited brand pricing power. The principal commercial product is oxycodone/acetaminophen, marketed historically as Percocet and now supplied mainly by generic manufacturers. Oxycodone terephthalate has no meaningful standalone U.S. commercial market and is better treated as a salt-form or formulation-related patent reference than as a separate revenue-generating drug.

U.S. revenue exposure is concentrated in generic manufacturers, contract suppliers, wholesalers, and government channels. The market has been reduced by opioid-prescribing controls, abuse-deterrence requirements, payer pressure, litigation settlements, manufacturing quotas, and declining utilization. A recovery to historical peak sales is unlikely.

What drugs contain acetaminophen and oxycodone hydrochloride?

The principal drug product is the immediate-release combination of acetaminophen and oxycodone hydrochloride.

Product category Active ingredients Typical strengths Commercial status
Generic oxycodone/acetaminophen tablets Acetaminophen and oxycodone HCl 300/2.5 mg, 300/5 mg, 300/7.5 mg, 300/10 mg, 325/5 mg, 325/7.5 mg, 325/10 mg Widely marketed generic
Percocet Acetaminophen and oxycodone HCl Historically 325/2.5 mg to 325/10 mg Brand presence, limited pricing power
Oral solution Acetaminophen and oxycodone HCl Concentration varies Niche hospital, pediatric and specialty use
Extended-release oxycodone products Oxycodone HCl without acetaminophen Product-specific Separate market from oxycodone/APAP

The combination is approved for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The FDA labeling carries boxed warnings for addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal, and interactions with benzodiazepines and other central nervous system depressants (FDA, 2024a).

Acetaminophen creates a separate safety constraint. Excessive cumulative exposure can cause severe liver injury. The 325 mg acetaminophen-per-tablet limit became commercially important because it reduced the acetaminophen load associated with commonly prescribed oxycodone combination products.

What is the market size and financial trajectory for oxycodone/acetaminophen?

The market has moved from a high-volume branded category to a low-margin generic category.

Public companies generally do not disclose revenue for individual oxycodone/acetaminophen strengths. The financial trajectory must therefore be assessed through prescription volume, generic pricing, opioid distribution controls, company filings, and litigation liabilities rather than a transparent product-level revenue series.

Market trajectory

Period Market condition Financial effect
1990s to mid-2000s Rapid expansion of opioid prescribing; strong branded and generic demand High volume growth and broad distributor participation
2007 to 2012 Rising misuse scrutiny and tighter prescribing controls Slower growth; rising compliance costs
2013 to 2017 Reformulation, lower opioid prescribing, public enforcement actions Declining branded demand and weaker pricing
2018 to 2021 Continued prescription contraction and settlement exposure Lower unit demand; higher legal and compliance costs
2022 to 2024 Mature generic market, persistent opioid controls, supply disruptions Stable-to-declining revenue with limited pricing recovery
2025 onward Continued generic supply, no material exclusivity moat Volume-led market with low expected margin expansion

The CDC reports that U.S. opioid prescribing peaked in 2011 and fell substantially thereafter. The decline has affected immediate-release oxycodone products, although demand remains material in postoperative care, oncology, trauma, palliative care, and selected chronic-pain populations (CDC, 2024).

For manufacturers, the commercial profile has four defining characteristics:

  1. Unit demand is structurally below historical levels.
  2. Generic competition limits price increases.
  3. Regulatory and supply-chain controls increase operating costs.
  4. Legal liabilities can exceed product-level operating profit.

The market remains commercially relevant because oxycodone is one of the most widely recognized prescription opioids and because hospitals, pharmacies, and wholesalers require continuing supply. That demand does not translate into high pharmaceutical margins.

Which companies sell acetaminophen and oxycodone hydrochloride?

The U.S. market is fragmented among generic manufacturers and repackagers. Product availability changes frequently because manufacturers add or withdraw National Drug Codes, face quota limits, or adjust production in response to enforcement and demand.

Commercial participants have included:

  • Endo Pharmaceuticals and its former branded Percocet business
  • Mallinckrodt
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Rhodes Pharmaceuticals
  • Teva Pharmaceuticals
  • Hikma, through generic oxycodone and combination products
  • Various FDA-approved generic manufacturers, repackagers and contract suppliers

Percocet historically provided brand recognition but did not retain the pricing protection associated with a patented product. Endo’s public reporting groups product revenues across broader categories, limiting precise assessment of Percocet-specific sales. Endo’s financial deterioration culminated in a Chapter 11 restructuring in 2022, reflecting the combined impact of debt, litigation, declining opioid economics and broader pharmaceutical pressures (Endo International, 2022).

Mallinckrodt also entered bankruptcy proceedings, with opioid liabilities and government claims forming part of its restructuring environment. Purdue Pharma’s bankruptcy litigation further changed the economics of branded opioid commercialization, even though Purdue’s core product exposure was primarily OxyContin rather than oxycodone/acetaminophen (U.S. Supreme Court, 2024).

What is the FDA and Orange Book status of oxycodone/acetaminophen?

Oxycodone/acetaminophen is an FDA-approved prescription drug subject to Schedule II controls under the Controlled Substances Act. Schedule II status prohibits refills and imposes heightened prescription, inventory, recordkeeping and distribution requirements.

The Orange Book contains approved oxycodone/acetaminophen products and their therapeutic-equivalence information. The commercial market is primarily supported by abbreviated new drug applications, meaning generic sponsors generally rely on established safety and efficacy findings rather than conducting full clinical-development programs (FDA, 2024b).

FDA market constraints

The most important regulatory constraints are:

  • Schedule II controlled-substance requirements
  • Opioid manufacturing quotas administered by the Drug Enforcement Administration
  • Risk Evaluation and Mitigation Strategy requirements for extended-release and long-acting opioids
  • State prescribing restrictions
  • Prescription monitoring programs
  • Pharmacist and payer utilization controls
  • FDA scrutiny of acetaminophen exposure
  • Distribution monitoring under the Controlled Substances Act

Immediate-release oxycodone/acetaminophen products do not have the same abuse-deterrent positioning as certain extended-release oxycodone products. That distinction affects prescribing, institutional purchasing and regulatory review.

What patents protect acetaminophen and oxycodone hydrochloride?

The immediate-release oxycodone/acetaminophen market has limited current patent protection. The core combination is old, and generic approval pathways have been available for many years.

Protection category Current commercial significance
Active ingredients No meaningful composition-of-matter exclusivity remaining
Immediate-release tablet combination Mature technology; generally exposed to generic competition
Acetaminophen dose selection Limited differentiation and weak standalone protection
Tablet excipients and manufacturing Potentially narrow protection, usually avoidable
Abuse-deterrent technology More relevant to extended-release oxycodone than immediate-release combinations
Method-of-use patents Limited practical value where broad pain indications are established
Manufacturing patents May protect process details but rarely block all generic supply

Are there Paragraph IV challenges?

Paragraph IV litigation is historically more important for branded extended-release oxycodone products and specialized formulations than for ordinary immediate-release oxycodone/acetaminophen tablets. Generic sponsors have long entered the immediate-release combination market through abbreviated applications.

A Paragraph IV certification can challenge an Orange Book-listed patent before expiry. For a mature oxycodone/acetaminophen product, the commercial significance of a new Paragraph IV dispute is generally low unless the patent covers a differentiated formulation, abuse-deterrent delivery system, or newly approved strength.

No current single patent appears to create a broad, durable barrier across the U.S. immediate-release oxycodone/acetaminophen market.

What is oxycodone terephthalate, and does it have a separate market?

Oxycodone terephthalate is a salt form of oxycodone. It has limited commercial visibility compared with oxycodone hydrochloride.

The principal market uses oxycodone hydrochloride or an oxycodone-equivalent dose. Oxycodone terephthalate may appear in patent disclosures, chemical claims, formulation descriptions or alternative salt-screening work. It should not be treated as an equivalent to a marketed product unless a specific FDA-approved product label identifies it as the active pharmaceutical ingredient.

Commercial implications of oxycodone terephthalate

Issue Assessment
Separate branded market No material U.S. market identified
Generic substitution Not automatically interchangeable with oxycodone HCl
Patent value Potentially relevant to salt, crystallinity or formulation claims
Regulatory pathway Would require product-specific FDA approval and equivalence analysis
Revenue contribution No separately reported revenue base
Manufacturing value Could involve different solid-state, stability or processing characteristics

The financial value of a terephthalate claim depends on whether it protects a required solid form or only an optional alternative salt. A patent covering one salt generally does not block all products using oxycodone hydrochloride. Conversely, a process patent may have value if the protected form improves stability, dissolution, manufacturability or abuse resistance.

How strong is the patent estate for the drug combination?

The patent estate is weak for the conventional immediate-release combination and stronger only where a company owns technically differentiated delivery or abuse-deterrent technology.

Patent-strength assessment

Patent layer Strength Reason
Core oxycodone/APAP composition Weak Long-established combination and extensive generic availability
Conventional tablet formulation Weak Numerous design-around options
Dose-specific claims Weak to moderate Narrow scope and limited blocking power
Terephthalate salt claims Variable Depends on claim breadth, validity and commercial use
Abuse-deterrent formulation Moderate to strong More difficult to replicate, but relevant mainly to specialized products
Manufacturing process Moderate Can create operational friction without blocking alternative processes
Method of use Weak to moderate Pain-treatment claims are difficult to enforce broadly

The primary competitive advantage is therefore supply reliability, regulatory compliance, hospital contracting, wholesaler access and cost control. Patent exclusivity is not the central value driver.

What patent litigation and settlement risks affect the market?

The opioid market has faced extensive federal, state and private litigation. Claims have included deceptive marketing, failure to control suspicious orders, public nuisance theories, distributor conduct, and injuries associated with opioid misuse.

The litigation environment has produced:

  • Large settlement payments by manufacturers and distributors
  • Bankruptcy restructurings
  • Compliance monitors and distribution controls
  • Restrictions on marketing practices
  • Higher insurance and legal costs
  • Reduced willingness to invest in branded opioid expansion

Settlement agreements have generally reduced the probability of uninterrupted litigation for individual companies but have imposed long-term cash obligations and operational restrictions. They do not restore the market’s prior pricing structure.

For a generic oxycodone/acetaminophen manufacturer, the major legal risk is usually not patent infringement. It is controlled-substance compliance, diversion, suspicious-order monitoring, product liability and participation in opioid settlement frameworks.

What generic launch scenarios exist?

Three launch scenarios are commercially relevant.

Base case: continued generic supply

Existing manufacturers maintain limited production, with demand concentrated in hospitals, surgery centers, retail pharmacies and pain specialists. Pricing remains competitive, and supply interruptions create periodic short-term opportunities.

Upside case: temporary shortage-driven pricing

A manufacturer gains share after a competitor exits, receives additional quota, or resolves a manufacturing issue. Pricing can improve temporarily, but new entrants and payer controls limit duration.

Downside case: regulatory or supply contraction

A manufacturer loses DEA quota, faces a warning letter, experiences a quality failure or exits the category. Remaining suppliers may gain volume, but total market demand remains constrained by prescribing controls.

A branded relaunch would face high barriers. The product lacks strong patent protection, and an entrant would need to justify a differentiated clinical, safety, packaging, adherence or abuse-deterrence proposition.

How does oxycodone/acetaminophen compare with other opioid markets?

Market Demand trend Patent position Margin profile Main risk
Oxycodone/APAP immediate release Declining to stable mature demand Weak Low generic margins Compliance and liability
Oxycodone extended release Smaller, specialized demand Formulation-dependent Higher if differentiated Abuse deterrence and litigation
Hydrocodone/APAP Large but mature Weak Low Prescribing restrictions
Tramadol combinations Broader lower-risk positioning Weak Generic Substitution and payer controls
Buprenorphine products Growth in addiction-treatment use Product-specific Better in some formulations Reimbursement and competition
Non-opioid analgesics Expanding substitution potential Varies Product-specific Clinical efficacy limitations

The strongest structural opportunity is substitution away from conventional opioid combinations. Growth areas include regional anesthesia, non-opioid postoperative protocols, NSAID-acetaminophen combinations, buprenorphine treatment products and digital prescribing controls.

What is the revenue exposure for pharmaceutical companies?

Revenue exposure is asymmetric. A generic manufacturer may receive meaningful sales from oxycodone/acetaminophen, but the product is rarely material enough to drive a diversified pharmaceutical company’s valuation unless it is part of a broader controlled-substance portfolio.

The main financial variables are:

  • Approved product count and available strengths
  • DEA quota allocation
  • Wholesale and hospital contracts
  • Product availability during competitor shortages
  • Manufacturing yield and quality performance
  • Litigation reserves
  • Controlled-substance compliance spending
  • Reimbursement and generic price erosion

For distressed opioid-focused companies, liability and debt service have often overwhelmed product gross profit. For diversified generic companies, oxycodone/acetaminophen is generally a portfolio product with modest revenue contribution and elevated compliance exposure.

Key Takeaways

  • The commercial market is primarily oxycodone hydrochloride combined with acetaminophen, not oxycodone terephthalate.
  • Immediate-release oxycodone/acetaminophen is a mature generic category with weak patent protection.
  • Percocet retains brand recognition but limited pricing power.
  • Prescription volume has declined materially from its historical peak.
  • Oxycodone terephthalate has no established standalone U.S. revenue market and is mainly relevant to salt and formulation patents.
  • Generic supply, DEA quotas, compliance systems and litigation exposure matter more than patent exclusivity.
  • A shortage-driven price increase is possible, but durable market expansion is unlikely.
  • Financial risk is concentrated in liability, compliance and supply continuity rather than loss of a core patent.

FAQs

Is oxycodone terephthalate approved by the FDA as a major marketed opioid?

Oxycodone terephthalate does not have the commercial visibility of oxycodone hydrochloride and is not the principal active ingredient in the widely marketed oxycodone/acetaminophen products.

Is Percocet still patent protected?

The core immediate-release oxycodone/acetaminophen product is not protected by a commercially meaningful composition patent. Generic versions have been widely available for years.

Can a generic manufacturer switch from oxycodone hydrochloride to oxycodone terephthalate?

No. A change in salt form can affect identity, specification, bioavailability and regulatory approval. The manufacturer would need product-specific FDA authorization.

Which factor is most likely to increase oxycodone/acetaminophen prices?

A temporary supply shortage caused by manufacturing disruption, quota limits or competitor withdrawal is more likely to increase prices than patent exclusivity.

Does acetaminophen create a separate commercial risk for oxycodone products?

Yes. Acetaminophen exposure creates liver-toxicity concerns and constrains dosing. That risk has encouraged lower-strength acetaminophen combinations and substitution with opioid-free analgesic regimens.

References

  1. Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps and prescribing data. https://www.cdc.gov
  2. Endo International plc. (2022). Annual report and Chapter 11 restructuring disclosures. https://www.endo.com
  3. U.S. Food and Drug Administration. (2024a). Oxycodone hydrochloride and acetaminophen prescribing information. https://www.accessdata.fda.gov
  4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
  5. U.S. Supreme Court. (2024). Harrington v. Purdue Pharma L.P., 603 U.S. 204. https://www.supremecourt.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.